SCCM Resource Library-Platform Trial of Whole Blood and Tranexamic Acid in Children With Severe Traumatic Bleeding

Platform Trial of Whole Blood and Tranexamic Acid in Children With Severe Traumatic Bleeding

Video Transcription

Video Summary

The presentation discusses the benefits of using low-titer group O whole blood over individual components for treating massive bleeding. Whole blood offers advantages like longer storage, fewer risks, and logistical benefits, potentially improving outcomes. The talk also covers transaminic acid (TXA) and its benefits in adults, though pediatric data is lacking. This has led to the MATIC-2 trial, which will compare whole blood to components and TXA to placebo in children, aiming to improve survival rates and understand mechanisms involved. The trial will span 20 centers and involve comprehensive mechanistic studies.

Asset Caption

45-Minute Session | Pediatric Traumatic Hemorrhagic Shock Consensus Conference Recommendations and Research Priorities

Meta Tag

Content Type Presentation

Membership Level Professional

Membership Level Select

Year 2024

Keywords

low-titer group O whole blood

massive bleeding treatment

transaminic acid (TXA)

MATIC-2 trial

pediatric survival rates

	Society of Critical Care Medicine 500 Midway Drive Mount Prospect, IL 60056 USA Phone: +1 847 827-6888 Fax: +1 847 439-7226 Email: support@sccm.org	Contact Us About SCCM Newsroom Advertising & Sponsorship DONATE	MySCCM LearnICU Patients & Families Surviving Sepsis Campaign Critical Care Societies Collaborative	GET OUR NEWSLETTER
© Society of Critical Care Medicine. All rights reserved. \| Privacy Statement \| Terms & Conditions The Society of Critical Care Medicine, SCCM, and Critical Care Congress are registered trademarks of the Society of Critical Care Medicine.